195 related articles for article (PubMed ID: 35176183)
1. Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.
Abedi E; Karimi M; Yaghobi R; Mohammadi H; Haghpanah S; Moghadam M; Bayat E; Rezvani A; Ramzi M
J Clin Lab Anal; 2022 Apr; 36(4):e24289. PubMed ID: 35176183
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
4. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
5. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
6. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
7. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
8. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
9. Inheritance of the chronic myeloproliferative neoplasms. A systematic review.
Ranjan A; Penninga E; Jelsig AM; Hasselbalch HC; Bjerrum OW
Clin Genet; 2013 Feb; 83(2):99-107. PubMed ID: 23094849
[TBL] [Abstract][Full Text] [Related]
10. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
[TBL] [Abstract][Full Text] [Related]
11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
12. Early and late stage MPN patients show distinct gene expression profiles in CD34
Baumeister J; Maié T; Chatain N; Gan L; Weinbergerova B; de Toledo MAS; Eschweiler J; Maurer A; Mayer J; Kubesova B; Racil Z; Schuppert A; Costa I; Koschmieder S; Brümmendorf TH; Gezer D
Ann Hematol; 2021 Dec; 100(12):2943-2956. PubMed ID: 34390367
[TBL] [Abstract][Full Text] [Related]
13. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
15. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
16. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
[TBL] [Abstract][Full Text] [Related]
18. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?
Scott LM; Rebel VI
Am J Hematol; 2012 Nov; 87(11):1028-36. PubMed ID: 22641564
[TBL] [Abstract][Full Text] [Related]
19. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
20. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]